Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06075394
Other study ID # xijingH-PF-202310
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2021
Est. completion date October 1, 2023

Study information

Verified date October 2023
Source Xijing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The influences of hypertension and antihypertensive medication on psoriasis have been long discussed. Given the limited and inconsistent evidence available, there is a need to further explore and clarify the relationship between hypertension and psoriasis, as well as to assess the relationship between antihypertensive medication use and the development or worsening of psoriasis symptoms. The aim of this retrospective study was to analyze data from electronic health records in a large population-based cohort, and the investigators aimed to investigate whether there was a significant association between hypertension and the use of related antihypertensive medications, such as ACEis, and psoriasis, and to explore potential confounders that may influence this association. Understanding the potential relationship between antihypertensive medication and psoriasis is critical, as this may have implications for the management of hypertension in patients with psoriasis or those at risk of developing the condition. This study will contribute to the existing body of evidence and provide valuable insights for clinicians to make informed decisions about the use of antihypertensive medication in this patient population, ultimately contributing to more effective prevention and management strategies for individuals affected by these diseases.


Description:

The investigators conducted a retrospective cohort study of psoriasis patients (≥18 years old) admitted as inpatients of Xijing hospital. Prior to the commencement of the survey, the investigators underwent collective training on data collection procedures to ensure the quality and reliability of the data. The study population included psoriasis patients aged 18 years or older who had been hospitalized at least once between 2012 and December 2022. Healthy individuals being randomly selected healthy individuals from a medical examination center. According to local ethics, the investigators have applied for exemption from written informed consent. Patients with psoriasis in the Department of Dermatology, Xijing Hospital of Air Force Medical University from December 2012 to December 2022 were consecutively collected. Inclusion criteria: (1) age ≥18 years; (2) Clear diagnosis of psoriasis. Exclusion criteria: (1) age <18; (2) Hypertension caused by conditions such as primary hypertension, hyperthyroidism, chronic renal insufficiency, or Cushing's syndrome, which are severe endocrine system diseases; (3) Patients with autoimmune diseases, severe cardiovascular, hepatic, renal, or other major organ disorders, as well as blood disorders and endocrine system diseases. The study collected various parameters, including baseline information such as ID number, gender, date of birth, medical history, and family history. Psoriasis-related data included age at first onset, date of diagnosis, duration of disease, frequency of relapse, psoriasis subtype, history of systemic/local medication, and comorbidities such as hypertension and dyslipidemia. Furthermore, clinical examination data and laboratory tests were conducted, which included measurements such as height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), PASI score (Psoriasis Area and Severity Index), fasting plasma glucose (FPG), total cholesterol (TC), total triglycerides, uric acid, neutrophil count (normal range 1.80-6.30 × 109/L), and lymphocyte count (normal range 1.00-4.80 × 109/L). It is important to note that all blood tests were conducted prior to any treatment. The above information was obtained from the Medical Record System of Xijing Hospital of Air Force Medical University.


Recruitment information / eligibility

Status Completed
Enrollment 9294
Est. completion date October 1, 2023
Est. primary completion date June 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Age =18 years; - Clear diagnosis of psoriasis Exclusion Criteria: - Age <18; - Hypertension caused by conditions such as primary hypertension, hyperthyroidism, chronic renal insufficiency, or Cushing's syndrome, which are severe endocrine system diseases; - Patients with autoimmune diseases, severe cardiovascular, hepatic, renal, or other major organ disorders, as well as blood disorders and endocrine system diseases.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Dermatology Derpartment of Xijing Hospital Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hypertension as a risk factor for psoriasis Hypertension has the potential to act as an underlying risk factor for the onset of psoriasis and has been identified as correlating with the frequency of recurrent psoriatic episodes. Information collection: over a span of 2 months
Secondary Antihypertensive Medication as a risk factor for psoriasis The use of antihypertensive medication may serve as a contributing factor to the risk of psoriatic relapse. Information collection: over a span of 2 months
See also
  Status Clinical Trial Phase
Completed NCT03236870 - A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Completed NCT00078819 - Etanercept (Enbrel®) in Psoriasis - Pediatrics Phase 3
Completed NCT04841187 - Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
Active, not recruiting NCT03927352 - The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis Phase 3
Completed NCT03284879 - Post-Marketing Surveillance Study of OTEZLA
Recruiting NCT06027034 - Effectiveness of a Digital Health Application for Psoriasis N/A
Not yet recruiting NCT06050330 - CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study N/A
Recruiting NCT05744466 - A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Completed NCT04149587 - A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Completed NCT01384630 - Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis Phase 2
Completed NCT03998683 - A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis Phase 3
Terminated NCT03556202 - A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06077331 - A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis Phase 2
Completed NCT04316585 - A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants Phase 1
Completed NCT04894890 - A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Completed NCT00358384 - Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 Phase 1
Completed NCT03757013 - A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Completed NCT05003531 - A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Phase 2